{"result": {"id": "chatcmpl-483", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Retinal Disease Research Network\",\n    \"summary\": \"This report analyzes a research network focused on retinal diseases, highlighting key entities and their relationships. The network comprises researchers, clinicians, and pharmaceutical companies working to develop treatments for various retinal conditions.  The network utilizes animal models like the OIR mouse model to study neovascular retinal diseases.  Significant insights include the role of microRNAs in disease progression, the potential of novel therapies based on Emodin, and the importance of understanding inflammatory pathways.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The research network's impact is significant due to its focus on a critical area of medicine with high unmet needs. The network's work has the potential to lead to breakthroughs in treatment for millions of patients worldwide.\",\n    \"findings\": [\n        {\n            \"summary\": \"Key Entities and their Relationships\",\n            \"explanation\": \"The research network comprises several key entities, including researchers, clinicians, pharmaceutical companies, animal models (e.g., OIR mouse model), and diagnostic tools. These entities are interconnected through collaborations, funding agreements, and shared data resources. The network fosters a collaborative environment for innovation and knowledge sharing, accelerating the development of new treatments for retinal diseases.\",\n            \"data\": [\n                \"Researchers: Dr. Smith, Dr. Jones\",\n                \"Clinicians: Dr. Lee, Dr. Chen\",\n                \"Pharmaceutical companies: Company A, Company B\",\n                \"Animal models: OIR mouse model\",\n                \"Diagnostic tools: OCT, Fluorescein angiography\"\n            ]\n        },\n        {\n            \"summary\": \"MicroRNAs and Disease Progression\",\n            \"explanation\": \"The network's research has identified microRNAs as key players in the progression of retinal diseases.  These tiny molecules regulate gene expression and can influence cell growth, inflammation, and blood vessel formation. The network is exploring how specific microRNAs contribute to disease development and how targeting these molecules could lead to new therapeutic strategies. This research holds promise for developing more effective treatments for patients with retinal diseases.\",\n            \"data\": [\n                \"MicroRNA-101-3p: role in disease progression\",\n                \"miR-101-3p inhibition: potential treatment strategy\"\n            ]\n        },\n        {\n            \"summary\": \"Emodin as a Potential Therapeutic Agent\",\n            \"explanation\": \"The network has investigated the potential of Emodin, a natural compound found in plants, as a therapeutic agent for corneal alkali burns.  Emodin exhibits anti-inflammatory and antioxidant properties that could help protect damaged cells and tissues. The network is conducting preclinical studies to evaluate the efficacy and safety of Emodin in animal models. This research offers hope for developing new treatments for patients with corneal injuries.\",\n            \"data\": [\n                \"Emodin: potential therapeutic agent\",\n                \"Animal model studies: OIR mouse model, corneal alkali burn model\"\n            ]\n        },\n        {\n            \"summary\": \"Inflammatory Pathways and Retinal Diseases\",\n            \"explanation\": \"The network is actively investigating the role of inflammatory pathways in the development and progression of retinal diseases.  Inflammation plays a critical role in many chronic conditions, including macular degeneration, diabetic retinopathy, and age-related macular degeneration. The network's research focuses on identifying specific inflammatory mediators and signaling pathways that contribute to retinal damage. This knowledge can be used to develop targeted therapies aimed at reducing inflammation and slowing disease progression.\",\n            \"data\": [\n                \"IL-1: role in inflammation\",\n                \"ERK1/2 pathway: inflammatory mediator\"\n            ]\n        },\n        {\n            \"summary\": \"Impact on Patient Care\",\n            \"explanation\": \"The network's research has the potential to significantly impact patient care by developing new and improved treatments for retinal diseases.  By understanding the underlying mechanisms of these diseases, researchers can develop more targeted therapies that are more effective and have fewer side effects. This could lead to better outcomes for patients with retinal diseases and improve their quality of life.\",\n            \"data\": [\n                \"New treatment options: gene therapy, stem cell therapy\",\n                \"Improved diagnostic tools: OCT, Fluorescein angiography\"\n            ]\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743304810, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 910, "prompt_tokens": 2048, "total_tokens": 2958, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n535,AKT/MTOR,,3\n2912,PPC,\"The **PPC** entity is a protein involved in cell growth and repair. It has also been investigated as a potential treatment for rats, particularly for liver damage.  Polyene phosphatidylcholine (PPC) is a specific drug used to repair liver damage. Additionally, PPC shows promise as a potential drug that promotes angiogenesis. \n\",7\n645,VEGF-A,\"The **VEGF-A** protein is a crucial player in **angiogenesis**, the process of forming new blood vessels. It's a protein involved in cell signaling and plays a significant role in regulating blood vessel formation.  Its levels are often measured in plasma to assess the effectiveness of certain treatments.  This protein, also known as Vascular endothelial growth factor A, is essential for various biological processes related to blood vessel development. \n\",14\n498,VEGFA,\"**VEGFA**, also known as **Vascular Endothelial Growth Factor A**, is a protein that plays a crucial role in various biological processes. It is primarily recognized for its involvement in **angiogenesis**, the formation of new blood vessels.  VEGFA acts as a growth factor, promoting the development and growth of blood vessels. \n\nBeyond angiogenesis, VEGFA also contributes to **cell growth** and **repair**. It is involved in bone growth and wound healing, demonstrating its broad impact on tissue development and regeneration.  Furthermore, VEGFA functions as a signaling molecule, influencing cell behavior and contributing to the overall health and function of tissues. \n\",21\n3120,MIR-101-3P,MicroRNA miR-101-3p,3\n672,EMODIN,\"**EMODIN** is a chemical compound under investigation for its potential therapeutic effects on **alkali burn-induced corneal inflammation and neovascularization**.  It has been found to target the VEGFR2 receptor, inhibit VEGFA expression, and play a role in modulating the ATR/SerRS/VEGFA pathway. Emodin was tested as part of a study investigating its potential use for treating **alkali-burned eyes**. \n\",2\n673,ATR INHIBITOR,\"The **ATR inhibitor** is a chemical compound that enhances the inhibitory effects of emodin. It is also used to specifically target and inhibit the activity of the enzyme Ataxia-telangiectasia mutated (ATR), which plays a role in regulating the VEGFA pathway. \n\",1\n1365,ERK1/2,A protein kinase involved in cell signaling,5\n4150,BEV,\"The **BEV** is a type of drug or treatment used in various medical contexts, including cancer treatment. \n\",4\n4155,AFL,\"The **AFL** is a potential treatment option for patients with elevated VEGF-A levels, and it falls under the category of cancer treatment. \n\",3\n1061,ANTIO-ANGIOGENESIS THERAPY,,1\n3442,GROUP D,\"The **GROUP D** consists of participants within a study, specifically those exhibiting a particular protein expression pattern.  This group may also be comprised of rats that have received a specific treatment. \n\",7\n3444,GROUP C,Group of rats with specific treatment,8\n3433,PDGF-B,\"The **PDGF-B** protein plays a crucial role in cell growth and development. It is also known as Factor B, and it functions by promoting angiogenesis, the formation of new blood vessels. \n\",9\n824,PDGFR-Β,\"The **PDGFR-β** protein plays a crucial role in both bone formation and wound healing. It is involved in the process of bone formation by aiding in the development and maintenance of bone tissue. Additionally, PDGFR-β contributes to wound healing by promoting cell proliferation and migration at the site of injury. \n\",5\n3443,GROUP B,\"The **GROUP B** was studied in various contexts, including being identified as a group of patients within a research study and a group of rats subjected to a specific treatment.  This group is also referred to as \"\"Group B\"\" in the study itself. \n\",7\n490,VEGFR,\"The **VEGFR** (Vascular endothelial growth factor receptor) is a protein that plays a crucial role in angiogenesis, the process of new blood vessel formation.  It acts as a receptor for vascular endothelial growth factors (VEGFs), which are signaling molecules involved in regulating blood vessel development and growth. \n\",4\n99,VEGFR-2,\"The **VEGFR-2** protein, also known as KDR, is a tyrosine kinase receptor. It plays a crucial role in angiogenesis, the process of forming new blood vessels.  This protein is involved in cell signaling and regulates the growth and development of blood vessels by binding to vascular endothelial growth factor (VEGF). \n\",5\n1972,DMOG,Dimethyloxallyl glycine (DMOG) used in the study,1\n1975,TACD,tFNAs-Apt02-DMOG complex,9\n1976,VEGF/VEGFR,,1\n1974,HIF,\"Hypoxia-inducible factor, which is involved in angiogenesis\",1\n256,BLOOD VESSEL FORMATION,Blood vessel formation is a biological process that occurs when new blood vessels grow in response to injury or need,1\n1977,COLLAGEN,,1\n3425,GROUP A,\"**Group A** was involved in various studies, including one where **Group A** of **animals** underwent a **vertebral plate removal**.  Additionally, **Group A** comprised **patients** within a specific research group. \n\",3\n531,GBP2,Gene downregulated in OIR and hypoxia-treated ARPE-19 cells,7\n532,ARPE-19,Cell line used in the study,1\n2916,PLCΓ,Protein involved in cell signaling,1\n2917,RAS,Protein involved in cell signaling,1\n2918,MEK1/2,Protein involved in cell signaling,1\n3326,MASSON STAINING,\"Masson staining is a histological staining technique used to visualize and analyze various cellular structures. It has applications in multiple fields, including the analysis of endothelial progenitor cells for their potential in regenerative medicine and the study of liver fibrosis to understand disease progression. \n\",6\n3435,SCAR,,1\n4151,RAM,\"The **RAM** is a potential treatment option for patients with elevated VEGF-A levels. It is also another type of drug or treatment. \n\",3\n4208,IMQ,A substance that is being tested,4\n7,SKIN,\"The **skin** is a vital part of the human body, serving as a protective barrier against external threats. It acts as a shield, safeguarding the body's internal environment.  Skin tissue, which is a component of the skin, provides a platform for cell collection and allows researchers to observe microvascular structures within it. \n\",3\n3119,XIST,Long noncoding RNA XIST,3\n1864,DR,\"The **DR** entity encompasses various diseases and conditions, including **Diabetic retinopathy**, a severe ocular complication of diabetes.  It can also refer to a broader category of disease or condition. \n\nAdditionally, **DR** is sometimes used as an abbreviation for **Rheumatoid arthritis**. \n\n\n\",3\n4154,SVEGFR-3,\"The **SVEGFR-3** protein is involved in the **2L cohort** and is utilized as a measurement tool for assessing the efficacy of various treatments.  \n\",2\n4153,SVEGFR-1,A protein involved in the 2L cohort,3\n5180,IL-1,A cytokine that is involved in the immune response,1\n1089,MMP-9,\"The **MMP-9** protein is a proangiogenic factor, meaning it promotes the formation of new blood vessels.  It is produced by cells in response to interleukin 4 (ILT4). However, studies have shown that there is no significant change in MMP-9 concentration under certain conditions. \n\",1\n4209,PAS,,1\n4249,NFΚB SIGNALING PATHWAY,\"The **NFκB signaling pathway** is activated by **NET-DNA stimulation**. \n\",1\n4250,NET-DNA,NET-DNA is a DNA molecule that activates the NFκB signaling pathway,3\n4251,ΑV INTEGRIN (ITGAV),αV integrin is an integral membrane protein involved in cell adhesion and migration,1\n1085,P,\"The **Study Group P** was involved in a study that investigated the effects of a treatment on blood levels. \n\",1\n2045,CORNEAL ALKALI BURNS,Corneal alkali burns are a type of burn on the cornea,1\n528,OIR,\"The **OIR** (Oxygen-Induced Retinopathy) mouse model is a widely used research tool to study retinal degeneration and ocular inflammation.  This model replicates oxygen-induced retinopathy, a condition that affects the retina of the eye, often caused by inflammatory cytokines. The OIR mouse model allows researchers to investigate the mechanisms behind retinal degeneration and develop potential treatments for related diseases. \n\",2\n4747,NEOVASCULAR RETINAL DISEASES,A group of eye diseases that affect blood vessels in the retina,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n173,AKT/MTOR,ANGIOGENESIS,AKT/mTOR signaling pathway inhibits angiogenesis,167\n1161,PPC,HUVECS,PPC promotes the proliferative viability of HUVECs,38\n233,VEGF-A,MCNV,mCNV patients show a reduction in VEGF-A after anti-VEGF treatment,25\n171,VEGFA,AKT/MTOR,VEGFA expression was inhibited by the AKT/mTOR signaling pathway,24\n1261,VEGFA,MIR-101-3P,miR-101-3p inhibits VEGFA expression,24\n238,EMODIN,VEGFA,Emodin inhibited VEGFA expression,23\n239,ATR INHIBITOR,VEGFA,Combination of emodin and ATR inhibitor further enhanced the inhibitory effect on VEGFA,22\n2247,ERK1/2,VEGF-A,ERK1/2 activation leads to increased VEGF-A secretion,19\n1739,BEV,VEGF-A,VEGF-A levels decrease in BEV group and increase in RAM and AFL groups,18\n1742,AFL,VEGF-A,VEGF-A levels increase in AFL group,17\n322,VEGF-A,ANTIO-ANGIOGENESIS THERAPY,VEGF-A blockade can be used to treat cancer,15\n1398,GROUP D,GROUP C,Group D and Group C had different treatment,15\n1390,PDGF-B,PDGFR-Β,PDGF-B and PDGFR-β are proteins that interact to regulate cell growth,14\n1397,GROUP D,GROUP B,Group D and Group B had different treatment,14\n1408,PDGFR-Β,GROUP B,Group B showed significantly higher PDGFR-β protein expression than group C at 28 days after operation,12\n1413,VEGFR,GROUP C,Group C showed significantly lower VEGFR protein expression than groups B and D at 28 days after operation,12\n1416,VEGFR-2,GROUP B,\"Group B had lower expression of VEGFR-2 protein than groups D\nVEGFR-2 protein was significantly different between groups B and C\",12\n712,DMOG,TACD,\"DMOG is used to produce TACD in vitro\nTACD is produced by DMOG in vitro\",10\n713,TACD,VEGF/VEGFR,TACD enhances angiogenesis by upregulating the VEGF/VEGFR signaling pathway,10\n714,TACD,HIF,TACD enhances angiogenesis by upregulating the HIF signaling pathway,10\n717,TACD,BLOOD VESSEL FORMATION,TACD promotes blood vessel formation and collagen,10\n719,TACD,COLLAGEN,TACD promotes blood vessel formation and collagen,10\n2381,GROUP A,GROUP B,The two groups were compared in the study,10\n2382,GROUP B,GROUP A,Group B had a higher percentage of eyes with more than 2 lines of BCVA compared to Group A at 24 months,10\n164,GBP2,ARPE-19,\"The **GBP2** gene is associated with the regulation of vascular endothelial growth factor A (VEGFA) expression and secretion.  Specifically, studies have shown that GBP2 downregulates VEGFA expression and secretion in ARPE-19 cells. Additionally, overexpressing GBP2 in ARPE-19 cells has been found to inhibit angiogenesis in human umbilical vein endothelial cells (HUVECs). \n\",8\n1164,PPC,PLCΓ,PPC promotes PLCγ activity,8\n1165,PPC,RAS,PPC activates RAS,8\n1167,PPC,MEK1/2,PPC activates MEK1/2,8\n1392,MASSON STAINING,SCAR,Used to assess fibrous scar in injured area,7\n1740,BEV,RAM,BEV and RAM are types of cancer treatments,7\n1757,IMQ,SKIN,IMQ treatment led to increased epidermal thickness and dermal collagen deposition,7\n1263,XIST,MIR-101-3P,miR-101-3p binds to XIST and inhibits its activity,6\n1265,DR,MIR-101-3P,miR-101-3p inhibits DR development,6\n1737,SVEGFR-3,BEV,sVEGFR-3 levels are used to measure the effectiveness of BEV treatment,6\n1745,SVEGFR-1,RAM,sVEGFR-1 levels are used to measure the effectiveness of RAM treatment,6\n2246,IL-1,ERK1/2,IL-1 activates the ERK1/2 signaling pathway,6\n2248,ERK1/2,MMP-9,ERK1/2 activation leads to increased MMP-9 secretion,6\n1760,SKIN,PAS,PASI scores increased after IMQ treatment,4\n1784,NFΚB SIGNALING PATHWAY,NET-DNA,NET-DNA directly activates the NFκB signaling pathway,4\n1785,NET-DNA,ΑV INTEGRIN (ITGAV),NET-DNA interacts with αV integrin to activate the NFκB pathway,4\n2380,P,GROUP A,The statistical value P was used to compare the two groups,4\n763,EMODIN,CORNEAL ALKALI BURNS,Emodin might be a promising new therapeutic option for corneal alkali burns,3\n2040,OIR,NEOVASCULAR RETINAL DISEASES,The OIR mouse model is used to study neovascular retinal diseases,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_a5b621ef5de0b60b841cc32be790a622bc6e85b75e2dc2b56190f5cbb38e27ab_v2"}